San Diego, United States
Toragen, Inc. is a biotechnology startup with a focused mission on developing innovative immunotherapies to combat viral-associated cancers. Their slogan, "Novel small molecule therapeutics targeting oncogenic viruses," encapsulates their strategic approach to addressing a critical medical need.
The company, established in 2016, boasts a team of industry leaders with extensive experience in early-stage biotechnology startups, translational drug development, and practice-changing Phase III clinical trials.
Toragen is currently in the final stages of a Phase I clinical trial for its lead compound designed to treat HPV-associated malignancies. To fuel their research and development efforts, the company has secured a notable $5.40M Seed Round investment from Paul Engler as of 30 September 2022.
With this recent investment and promising clinical progress, Toragen, Inc. is poised to make significant strides in the biotechnology industry. They anticipate that the investor funding will further accelerate their pursuit of groundbreaking treatments for viral-associated cancers.
